(Q25254962)

6 July 2017

title

Recent developments in targeting access to high cost medicines in Australia (English)

1 reference

6 July 2017

0 references

Richard O Day

4

0 references

author name string

Christine Y Lu

series ordinal

1

1 reference

6 July 2017

Jan Ritchie

series ordinal

2

1 reference

6 July 2017

Kenneth M Williams

series ordinal

3

1 reference

6 July 2017

language of work or name

English

0 references

publication date

23 November 2005

1 reference

Australia and New Zealand Health Policy

6 July 2017

published in

1 reference

6 July 2017

volume

2

1 reference

6 July 2017

issue

1

0 references

page(s)

28

1 reference

National Prescribing Service: creating an implementation arm for national medicines policy

6 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1325248

Considerations with the use of biological therapy in the treatment of rheumatoid arthritis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1325248

Public involvement in health care

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1325248

Drug reimbursement in Finland—a case of explicit prioritising in special categories

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1325248

Involving the general public in priority setting: experiences from Australia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1325248

Priority setting for new technologies in medicine: qualitative case study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1325248

Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1325248

The Australian National Medicinal Drug Policy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1325248

Reimbursement decisions in health policy--extending our understanding of the elements of decision-making.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1325248

Access to high cost drugs in Australia

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1325248

Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1325248

Patient and public involvement

28 November 2018

1 reference

12 December 2020

Subsidised access to TNF-alpha inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defensible?

1 reference

12 December 2020

Subsidised access to TNF alpha inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defensible?

1 reference

12 December 2020

The subsidy of pharmaceuticals in Australia: processes and challenges

1 reference

12 December 2020

Identifiers

DOI

10.1186/1743-8462-2-28

1 reference

Dimensions Publication ID

6 July 2017

0 references

1 reference

6 July 2017

1 reference